|
相關減重藥品價格比較(以在美國的價格比較)：
Wegovy(約1350美元{約台幣41850}) >Saxenda(約1300美元{約台幣40300}) >Rybelsus(約920美元{約台幣28520}) >Contrave(約550美元{約台幣17050}) >Qsymia(約200美元{約台幣6200}) 參考資料: Rybelsus in goodrx Saxenda in goodrx Contrave in goodrx Wegovy in goodrx Qsymia in goodrx 若有任何問題或需要領取相關藥物之疑問者，都歡迎加官方LINE帳號(點此即可加入)詢問。
0 評論
2022最新美國腸胃科醫學會(ACG)減重藥物治療指引❗
🦁美國腸胃科醫學會(ACG)在2022年10月底發表了最新的減重藥物治療指引，讓減重藥物的使用，在實證醫學上更確立了角色。文中提到，減重藥物搭配調整飲食生活習慣，對於肥胖且有共病的人，可以達到更好的減重效果。 文中提到使用的藥物有四種： 1️⃣ Semaglutide (Wegovy; 註: 目前台灣只有用於治療糖尿病的Ozempic, 胰妥讚及口服的Rybelsus瑞倍適) 2️⃣ Liraglutide (Saxenda, 善纖達) 3️⃣ Phentermine-topiramate (台灣未上市) 4️⃣ Naltrexone-bupropion (Contrave, 康纖芙) 根據文中指出，統合多篇臨床試驗資料，減重效果依序為semaglutide [10.8%] > phentermine-topiramate [8.5%] > liraglutide [4.8%] (善纖達) > Naltrexone-bupropion [3.0%] (康纖芙) [上述排列依臨床試驗平均下降體重%] 🧑⚕️減重藥物不是哪一個比較好，而是選擇適合自己的輔助減重藥品才是最重要的！ [只是輔助，不是依賴] 例如：想要瘦比較多的可以選semaglutide；有調整每日食慾需求的可以選Saxenda；✌又想調控食慾又不喜歡打針或是也有戒菸需求的可以選Contrave 相關減重藥品價格比較：請查看下一篇文章 參考資料: Gastroenterology 2022;163:1198–1225 若有任何問題或需要領取相關藥物之疑問者，都歡迎加官方LINE帳號(點此即可加入)詢問。 噁心、便秘(19%)、頭痛(17%)、嘔吐、頭暈(10%)、失眠(9%)、口乾(8%)、腹瀉。
參考資料：康纖芙仿單 若有任何問題或需要領取相關藥物之疑問者，都歡迎加官方LINE帳號(點此即可加入)詢問。 台灣成人過重的盛行率，自2013年以來男女合計已超過40%；而國人十大死因中，與肥胖相關的疾病高達八項，肥胖成為國人不得不重視的健康議題。 當肥胖及三高患者至門診求助，應建議個案先改善生活習慣，也就是改變飲食及運動習慣，藉此減少熱量攝取、增加熱量消耗。然而減重後容易復胖，有研究證實這跟荷爾蒙和酵消化酵素的代償有關，使得減重相當不易。 臨床上若是病患BMI≧30kg/m2或是BMI≧27 kg/m2且至少有一種合併症(高血壓、第二型糖尿病或血脂異常)，可使用減重藥物作為低卡飲食及適當運動的輔助治療。 目前三種TFDA認證的減重藥物
若有任何問題或需要領取相關藥物之疑問者，都歡迎加官方LINE帳號(點此即可加入)詢問。 參考資料： Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options Current treatments for obesity   雄性禿與圓禿有甚麼差別呢？ 能治療圓禿，那能治療雄性禿嗎？ Two Phase 3 Trials of Baricitinib for Alopecia Areata List of authors. Brett King, M.D., Ph.D., Manabu Ohyama, M.D., Ph.D., Ohsang Kwon, M.D., Ph.D., Abraham Zlotogorski, M.D., Justin Ko, M.D., Natasha A. Mesinkovska, M.D., Ph.D., Maria Hordinsky, M.D., Yves Dutronc, M.D., Wen-Shuo Wu, M.D., Jill McCollam, Pharm.D., Chiara Chiasserini, Sc.D., Guanglei Yu, Ph.D., et al., for the BRAVE-AA Investigators* Abstract BACKGROUND Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokine signaling implicated in the pathogenesis of alopecia areata. METHODS We conducted two randomized, placebo-controlled, phase 3 trials (BRAVE-AA1 and BRAVE-AA2) involving adults with severe alopecia areata with a Severity of Alopecia Tool (SALT) score of 50 or higher (range, 0 [no scalp hair loss] to 100 [complete scalp hair loss]). Patients were randomly assigned in a 3:2:2 ratio to receive once-daily baricitinib at a dose of 4 mg, baricitinib at a dose of 2 mg, or placebo. The primary outcome was a SALT score of 20 or less at week 36. RESULTS We enrolled 654 patients in the BRAVE-AA1 trial and 546 in the BRAVE-AA2 trial. The estimated percentage of patients with a SALT score of 20 or less at week 36 was 38.8% with 4-mg baricitinib, 22.8% with 2-mg baricitinib, and 6.2% with placebo in BRAVE-AA1 and 35.9%, 19.4%, and 3.3%, respectively, in BRAVE-AA2. In BRAVE-AA1, the difference between 4-mg baricitinib and placebo was 32.6 percentage points (95% confidence interval [CI], 25.6 to 39.5), and the difference between 2-mg baricitinib and placebo was 16.6 percentage points (95% CI, 9.5 to 23.8) (P<0.001 for each dose vs. placebo). In BRAVE-AA2, the corresponding values were 32.6 percentage points (95% CI, 25.6 to 39.6) and 16.1 percentage points (95% CI, 9.1 to 23.2) (P<0.001 for each dose vs. placebo). Secondary outcomes for baricitinib at a dose of 4 mg but not at a dose of 2 mg generally favored baricitinib over placebo. Acne, elevated levels of creatine kinase, and increased levels of low- and high-density lipoprotein cholesterol were more common with baricitinib than with placebo. CONCLUSIONS In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. Longer trials are required to assess the efficacy and safety of baricitinib for alopecia areata. (Funded by Eli Lilly under license from Incyte; BRAVE-AA1 and BRAVE-AA2 ClinicalTrials.gov numbers, NCT03570749. opens in new tab and NCT03899259. opens in new tab.) 參考資料： Two Phase 3 Trials of Baricitinib for Alopecia Areata 降血壓藥到底白天吃要比較好還是晚上吃比較好？Evening dosing of blood pressure medication not better than morning dosing8/29/2022 降血壓藥到底白天吃要比較好還是晚上吃比較好？ 這個問題一直以來都個有說法，一直到最近的研究總算有個比較清楚的結論。 那就是一樣好。 降血壓藥在白天吃跟在晚上吃一樣。 TIME trial presented in a Hot Line Session today at ESC Congress 2022 26 Aug 2022 Topic(s): Cardiovascular PharmacotherapyBarcelona, Spain – 26 Aug 2022: A pragmatic randomised trial in more than 21,000 patients with high blood pressure followed for over five years has concluded that protection against heart attack, stroke and vascular death is not affected by whether antihypertensive medications are taken in the morning or evening. The late breaking research is presented in a Hot Line session today at ESC Congress 20221 and contradicts previous findings that suggested a very large cardiovascular benefit of night-time dosing.2 More than one billion people have high blood pressure worldwide.3 High blood pressure is the leading global cause of premature death, accounting for almost ten million deaths in 2015, of which 4.9 million were due to ischaemic heart disease and 3.5 million were due to stroke. Nocturnal blood pressure is a better predictor of cardiovascular outcomes than daytime blood pressure, and there is previous evidence that antihypertensive drugs taken in the evening rather than in the morning reduced night-time blood pressure to a greater extent.4 The Hygia study2 previously indicated a protective effect of nocturnal dosing on cardiovascular events, but this study has attracted criticism.5 TIME was a large prospective, randomised trial conducted to test whether evening dosing of antihypertensive medication improved major cardiovascular outcomes compared with morning dosing.6 Adults taking at least one antihypertensive medication and with a valid email address were recruited by advertising in the community, from primary and secondary care, and from databases of consented patients in the UK. After participants had signed up on the TIME website (http://www.timestudy.co.uk) and their eligibility was confirmed, they were randomised 1:1 to take their usual antihypertensive medication in the morning or the evening. The composite primary endpoint was hospitalisation for nonfatal myocardial infarction or nonfatal stroke, or vascular death, in the intention-to-treat population. Information on hospitalisations and deaths was obtained from participants by email and through record linkage to national databases and further data was gathered from family doctors and hospitals and independently adjudicated by a committee blinded to allocated dosing time. A total of 21,104 patients were randomised, 10,503 to evening dosing and 10,601 to morning dosing. The average age of participants was 65 years, 58% were men and 98% were white. The median follow-up duration was 5.2 years but some were in the study for over nine years. The primary endpoint occurred in 362 (3.4%) participants in the evening dosing group (0.69 events per 100 patient years) and 390 (3.7%) in the morning dosing group (0.72 events per 100 patient years), giving an unadjusted hazard ratio of 0.95 (95% confidence interval 0.83–1.10; p=0.53). The results did not vary in pre-specified subgroup analyses. Taking medication in the evening was not harmful. Principal investigator Professor Thomas MacDonald of the University of Dundee, UK said: “TIME was one of the largest cardiovascular studies ever conducted and provides a definitive answer on the question of whether blood pressure lowering medications should be taken in the morning or evening. The trial clearly found that heart attack, stroke and vascular death occurred to a similar degree regardless of the time of administration. People with high blood pressure should take their regular antihypertensive medications at a time of day that is convenient for them and minimises any undesirable effects.” ENDS 參考資料： Evening dosing of blood pressure medication not better than morning dosing  一次簡單搞懂減重藥「康纖芙」 CONTRAVE(BUPROPION AND NALTREXONE)
ContraveⓇ（bupropion/naltrexone）是2014年FDA核准上市的複方製劑，適合同時需要戒菸與減重者，不建議當作減重第一線藥物。Bupropion是非典型抗憂鬱劑，naltrexone是單純鴉片類受體拮抗劑，bupropion/naltrexone確實的作用機轉尚未被完全了解，可能是藉由增加下視丘促黑素皮質素神經元（食慾調節中心）的放電速率來調節減少食物的攝取。 Bupropion/naltrexone減重效果與lorcaserin相似，但是有較多的副作用。研究指出，相較於安慰劑組，服用bupropion/naltrexone可以顯著降低體重（-5~6% vs -1.3%），但是血壓上升與心跳快的副作用比例也較高。常見副作用有噁心（30%）、頭痛（14%）及便秘（15%）等。患有癲癇、未良好控制的高血壓、長期使用鴉片藥物、14天內使用過MAOI藥品者應避免使用。 參考資料： FDA 藥師週刊 Naltrexone/Bupropion ER (Contrave) 此文章詳細內容依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 若有任何問題或需要領取相關藥物之疑問者，都歡迎加官方LINE帳號(點此即可加入)詢問。 一次簡單搞懂圓形禿新藥OLUMIANT (BARICITINIB)
此藥品原為治療類風濕性關節炎。 參考資料： FDA FDA Approves First Systemic Treatment for Alopecia Areata 此文章詳細內容依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 友華進軍減重市場 新機轉口服新藥獲TFDA核准 (圖為友華生技執行長蔡孟霖，圖片來源：本刊資料中心)
日前，友華生技(4120)引進美國最新機轉減重口服藥Contrave「康纖芙」，三月份剛取得國內衛福部藥證，預計今年下半年上市，這是友華進軍減重市場的首支減重產品。 友華去年與康霈生技合作代理CBL-514溶脂注射劑新藥，今年取得口服新藥的藥證，友華生技執行長蔡孟霖表示，Contrave「康纖芙」的作用機轉在於能將降低飢餓感與對食物的渴望，達到減重目標，根據國外文獻報告，在第四週起便可達到較安慰劑更顯著的體重減輕，是國內最新機轉的口服新藥，上市後將提供全新治療選擇。 Contrave「康纖芙」於2014年就陸續在美國、歐盟、加拿大及澳洲核准上市，也已在亞洲新加坡及韓國上市，今年國內上市核准用於體重控制，做為低熱量飲食、以及增加體能活動的輔助療法，適用於身體質量指數BMI≧30的肥胖患者，或是BMI≧27、且病人至少有一項體重相關共病症。 上述文字引述環球生技 6 月 13 日，美國食品藥物管理局（FDA）宣佈核准禮來（Eli Lilly）的 Olumiant (baricitinib) 口服藥物，用於治療患有嚴重圓禿（alopecia areata）成年患者。圓禿是一種常見因自體免疫異常導致的皮膚落髮症狀。 FDA 核准 Olumiant 的關鍵進展，帶來首個圓禿的全身性治療（systemic treatment）而非局部性治療方法。FDA 皮膚科藥物評估和研究中心 Kendall Marcus 主任表示，此項批准有助於滿足嚴重圓禿者的重大未滿足治療需求。 JAK 抑制劑可減緩毛囊發炎、減少落髮 圓禿是一種自體免疫疾病，因為免疫系統的淋巴球異常攻擊毛囊，毛囊急性發炎導致的落髮現象。全美每年約有超過 30 萬人飽受圓禿所擾，知名影帝 Will Smith 妻子 Jada Pinkett Smith 也是患者之一。 現有圓禿療法包含局部塗抹類固醇藥物，產生抗發炎作用，例如嬌生（J&J）的 Rogaine，其含有 minoxidil 也是生髮水中主要成分；另外有些類固醇藥物則是注射劑形式。而 Olumiant 是一種 JAK 抑制劑，透過阻斷發炎反應的酵素活性達到減緩落髮效果。 兩項 Olumiant 的臨床試驗（Trial AA-1, Trial AA-2），招募落髮受試者為落髮至少 50% 達 6 個月以上患者，他們每天分別接受安慰劑、2/4 mg Olumiant 治療。Trial AA-1 結果顯示 2/4 mg Olumiant 治療組分別有 22%、35% 獲得足夠的頭髮覆蓋，安慰劑組僅 5%。Trial AA-2 中 2/4 mg Olumiant 治療組分別有 17%、32% 獲得足夠的頭髮覆蓋，安慰劑組僅 3%。整體而言，至少一半以上受試者在治療第 36 週時，出現 80% 以上頭髮覆蓋改善情形。 Olumiant 相繼核准用於類風濕關節炎、COVID-19 治療 Olumiant 是禮來與美國公司 Incyte 自 2008 年起授權合作，共同研發的 JAK 抑制劑藥物，目前已成功累積數項適應症。 2018 年 6 月，FDA 首度批准 Olumiant 作為成年中至重度類風濕關節炎（rheumatoid arthritis）療法。適用對象是以接受過一種以上 TNF 抑制劑者，需特別注意的是 Olumiant 不可與其他 JAK 抑制劑聯用。 今年 5 月，FDA 再許可 Olumiant 用於住院且需氧氣支持的特定重度新冠患者。先前 FDA 已通過Olumiant 的緊急使用授權（EUA），正式核准後 Olumiant 則成為第一個、且是唯一一款重症新冠的 JAK 抑制劑藥物。 同時，近年 FDA 對 JAK 抑制劑藥物也給予相當關注，揭露該類免疫抑制藥物可能有引發心臟病、中風等副作用風險。去年 FDA 公布更新 3 款 JAK 抑制劑藥物的黑盒警示（black box warning），除了包含禮來的 Olumiant，另外還有輝瑞（Pfizer）的 Xeljanz、與艾伯維（Abbvie）的 Rinvoq；Xeljanz、Rinvoq 都是類風濕關節炎用藥。 上述文字來自GENE ONLINE 以下內容僅轉載Healio.com 不代表新德大藥局之任何意見以下內容摘自Healio.com SURMOUNT-1: Adults achieve weight loss of 16% or more at 72 weeks with tirzepatide Adults with overweight or obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide achieved a mean weight loss of at least 16% at 72 weeks, according to topline results from the SURMOUNT-1 clinical trial. In a phase 3 trial with 2,539 participants, tirzepatide (Eli Lilly) met both primary endpoints for mean percentage change in body weight from baseline and percentage of participants with a 5% reduction in body weight compared with placebo. Adults randomly assigned to receive tirzepatide had a mean weight loss of 16% with 5 mg, 21.4% with 10 mg, and 22.5% with 15 mg compared with a 2.4% mean weight loss for those assigned placebo. Of those assigned tirzepatide, 89% achieved a weight loss of at least 5% compared with 28% in the placebo group. Louis J. Aronne, MD, FACP, DABOM Aronne is the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine at New York-Presbyterian/Weill Cornell Medical Center and investigator in the SURMOUNT-1 trial. “This study shows that highly significant weight loss, in line with what is achieved with surgical procedures, can be achieved with tirzepatide,” Louis J. Aronne, MD, FACP, DABOM, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine at New York-Presbyterian/Weill Cornell Medical Center and investigator in the SURMOUNT-1 trial, told Healio. “The mean BMI was about 38 kg/m2 to start and was reduced to about 30 kg/m2 with many subjects getting into the normal range.” Tirzepatide met all key secondary endpoints, with 55% of those receiving 10 mg and 63% of those receiving 15 mg achieving a body weight reduction of at least 20% compared with 1.3% of the placebo group. In an additional secondary endpoint analysis not controlled for type 1 error, 32% of those receiving 5 mg tirzepatide lost at least 20% of body weight, according to the release. “For perspective, a 5% weight loss reduces the risk of developing diabetes by 50%, and a 10% weight loss reduces it by 80%,” Aronne said. “Lap band produces about 17% weight loss, and sleeve gastrectomy 25% mean weight loss. The gap between diets and bariatric surgery is being filled by medical therapy.” The safety and tolerability profile for tirzepatide was similar to that those of other incretin-based therapies approved for obesity treatment. Most side effects were mild to moderate; the most common were nausea, diarrhea, constipation and vomiting. Participants with prediabetes at the start of the trial will remain enrolled for an additional 104 weeks beyond the initial 72-week trial period to evaluate the impact of body weight and potential differences in type 2 diabetes progression with tirzepatide compared with placebo. The SURMOUNT-1 results will be presented at an upcoming medical meeting and submitted to a peer-reviewed journal, according to the release. Additional studies are ongoing. 根據 SURMOUNT-1 臨床試驗的一線結果，每週服用一次 GIP/GLP-1 受體激動劑替西帕肽的超重或肥胖成人在 72 週時平均體重減輕至少 16%。
在一項有 2,539 名參與者的 3 期試驗中，tirzepatide (Eli Lilly) 達到了兩個主要終點，即體重相對於基線的平均百分比變化和與安慰劑相比體重減輕 5% 的參與者百分比。隨機分配接受 tirzepatide 的成年人平均體重減輕 16%（5 毫克）、21.4%（10 毫克）和 22.5%（15 毫克），而安慰劑組平均體重減輕 2.4%。在分配替西帕肽的患者中，89% 的患者體重減輕至少 5%，而安慰劑組為 28%。 “這項研究表明，使用 tirzepatide 可以顯著減輕體重，與外科手術所達到的效果一致，”威爾康奈爾大學 Sanford I. Weill 代謝研究教授Louis J. Aronne 醫學博士、FACP、DABOM紐約長老會/威爾康奈爾醫學中心的醫學和 SURMOUNT-1 試驗的調查員告訴 Healio。“開始時的平均 BMI 約為 38 kg/m 2 ，隨著許多受試者進入正常範圍，隨後降至約 30 kg/m 2。 ” Tirzepatide 達到了所有關鍵的次要終點，55% 的接受 10 mg 的患者和 63% 的接受 15 mg 的患者實現了至少 20% 的體重減輕，而安慰劑組為 1.3%。根據發布的消息，在另一項未對 1 型錯誤進行控制的次要終點分析中，接受 5 mg 替西帕肽的患者中有 32% 的人體重減輕了至少 20%。 “從長遠來看，減重 5% 可將患糖尿病的風險降低 50%，減重 10% 可降低 80%，”Aronne 說。“膝帶可減輕約 17% 的體重，袖狀胃切除術平均減輕 25% 的體重。飲食和減肥手術之間的差距正在通過藥物治療來填補。” 替西帕肽的安全性和耐受性與其他批准用於肥胖治療的腸促胰島素療法相似。大多數副作用為輕度至中度；最常見的是噁心、腹瀉、便秘和嘔吐。 在試驗開始時患有前驅糖尿病的參與者將在最初的 72 週試驗期之後再加入 104 週，以評估體重的影響以及 tirzepatide 與安慰劑相比對 2 型糖尿病進展的潛在差異。 據新聞稿稱，SURMOUNT-1的結果將在即將召開的醫學會議上公佈，並提交給同行評審的期刊。其他研究正在進行中。 此文章詳細內容依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 OZEMPIC 4MG/3ML SOLUTION FOR INJECTION胰妥讚注射劑藥品缺藥 台灣諾和諾德藥品股份有限公司表示，本品項因供應問題導致缺藥，預計111年12月底恢復供應。 因此，請慢性處方箋上有此品項者，到原處方醫院領取慢性處方箋。 造成困擾，敬請見諒。  另外，目前有很多人使用胰妥讚作為減重用藥，甚至在沒有醫師開立處方下，就私下使用，目前胰妥讚的藥證內容只限於糖尿病患者用藥，並沒有經衛福部核可做為
"用於體重控制，做為低熱量飲食及增加體能活動外之輔助療法。" 因此，即使是醫師開立胰妥讚做為減重輔助藥品，也算是藥品仿單標示外之適應症使用。 至於甚麼是藥品仿單標示外之適應症使用，可以參考以下影片或文章。 影片：一次搞懂藥品仿單標示外使用（Off Label Use） 文章：一次搞懂藥品仿單標示外使用（Off Label Use） 若有任何問題或需要領取相關藥物之慢性處方箋者，都歡迎加官方LINE帳號(點此即可加入)詢問。 FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 (自 2014 年以來，FDA 首次批准用於慢性體重管理的新藥治療) Wegovy 於2021 年 6 月 4 日通過FDA許可作為減重的針劑。 詳細內容可以參考FDA的文章或是諾和諾德的官方網站。  此文章詳細內容依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。
恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 Rybelsus 瑞倍適(semaglutide)在2019年9月20日通過美國FDA的藥品許可，成為全世界第一個口服的GLP-1降血糖藥。 目前核可的適應症為第二型糖尿病的用藥，未來在減重輔助治療的臨床試驗中，有機會得到不錯的臨床數據。 同成分的針劑： 1、OZEMPIC於2017年12月5日取得第二型糖尿病的適應症。 2、WEGOVY於2021年6月4日取得減重輔助治療適應症。 參考資料： FDA FDA approves first oral GLP-1 treatment for type 2 diabetes FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 此文章詳細內容依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。  結論 同樣一週一次注射的Tirazepatide與Semaglutide比較，Tirazepatide能下降更多的血糖與體重，而副作用並沒有高更多。 附註：禮來(Eli Lilly) 預計2022年4月對於tirzepatide之關鍵臨床試驗發布結果。 參考資料： 1、Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes 2、‘Stunning’ Twincretin Beats Semaglutide in Type 2 Diabetes 此文章詳細內容依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。   近期有太多人詢問
以SEMAGLUTIDE成份 核准的藥品包含 1、針劑：OZEMPIC 宜妥讚 2、口服藥：RYBELSUS 瑞倍適錠 到底可否用來減肥(重)呢？ 當然更多人詢問， 到底在臨床上用來減重的效果好不好？ 此文章依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 今天看到死亡個案出現一個「無慢性病史」的30幾歲女性，怎麼會這樣呢？ 沒多久就就看到這個報導， 30多歲女「快速死」PCR陰轉陽5天不治 體重90公斤致病情惡化 「肥胖症」其實早就被世界衛生組織正名是一種「脂肪相關慢性疾病」（Adiposity-Based Chronic Disease (ABCD) )積極治療肥胖根本不是外觀的問題，而是跟治療高血壓、糖尿病一樣，刻不容緩的事情。 在今年四月前新冠死亡率居全球之冠的捷克，每10萬人就有229人染疫喪命，而捷克的肥胖是全歐洲之冠，女性57%肥胖、男性71%肥胖，10個新冠患者有8個肥胖， 新冠死亡率被認為跟肥胖有明確且嚴重的相關性。 台灣目前是亞洲的肥胖冠軍........ 一些區域的研究，發現糖尿病會讓新冠病毒死亡的風險多了8倍，而肥胖可以讓死亡風險高達10倍。 如果控制血糖跟血壓很重要，那控制體重難道不是更重要嗎？ 研究證實，當肥胖者減少5%以上體重(如成人90公斤，減少5公斤)，就可以為健康帶來許多益處，高血壓、糖尿病等與肥胖相關疾病將可改善。 強烈建議以後新冠肺炎死亡病例的「慢性病史」，麻煩一定要把「肥胖」列入在裡面，才能讓民眾正視自己的健康問題！ 對於醫療人員來說處理肥胖，也是非常緊急的事，當BMI超過25時，每增加1單位，相對所有原因死亡率風險便增加9％，包括心因性猝死風險，是的，先不提快樂缺氧了，每個BMI在30以上的人，我都會嚴正告訴他猝死的風險，千萬不要因為自己年輕、或是血液報告尚可，就忽視了隱藏的風險。  也可以參考美國疾病管制局 www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html OverviewAdults of any age with the following conditions can be more likely to get severely ill from COVID-19. Severe illness means that a person with COVID-19 may need:
Preventive measures for COVID-19 (including vaccination, wearing a mask and social distancing) are important especially if you are older or have multiple or severe health conditions. You can learn about CDC’s COVID-19 vaccine recommendations, including how medical conditions and other factors inform recommendations, here. Note: The list below does not include all potential medical conditions that could make you more likely to get severely ill. Rare medical conditions may not be included below. However, a person with a condition that is not listed may still be in more danger from COVID-19 than persons of similar age who do not have the condition and should talk with their healthcare provider. Top of PageMedical Conditions in Adults
Get more information:
Get more information: Chronic lung diseases, including COPD (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertensionChronic lung diseases can make you more likely to get severely ill from COVID-19. These diseases may include:
Get more information: Diabetes (type 1 or type 2)Having either type 1 or type 2 diabetes can make you more likely to get severely ill from COVID-19. Get more information:
Get more information: Heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension)Having heart conditions such as heart failure, coronary artery disease, cardiomyopathies, and possibly high blood pressure (hypertension) can make you more likely to get severely ill from COVID-19. Get more information: HIV infectionHaving HIV (Human Immunodeficiency Virus) can make you more likely to get severely ill from COVID-19. Get more information: Immunocompromised state (weakened immune system)Having a weakened immune system can make you more likely to get severely ill from COVID-19. Many conditions and treatments can cause a person to be immunocompromised or have a weakened immune system. Primary immunodeficiency is caused by genetic defects that can be inherited. Prolonged use of corticosteroids or other immune weakening medicines can lead to secondary or acquired immunodeficiency. Get more information:
Get more information:
Get more information:
Get more information:
Get more information: Smoking, current or formerBeing a current or former cigarette smoker can make you more likely to get severely ill from COVID-19. If you currently smoke, quit. If you used to smoke, don’t start again. If you’ve never smoked, don’t start. Get more information:
Get more information: Stroke or cerebrovascular disease, which affects blood flow to the brainHaving cerebrovascular disease, such as having a stroke, can make you more likely to get severely ill from COVID-19. Get more information: Substance use disordersHaving a substance use disorder (such as alcohol, opioid, or cocaine use disorder) can make you more likely to get severely ill from COVID-19. Get more information:
Actions You Can TakeIn general, the older you are, the more health conditions you have, and the more severe the conditions, the more important it is to take preventive measures for COVID-19 such as vaccination, wearing a mask , social distancing, and practicing hand hygiene. Please contact your state, tribal, local, or territorial health department for more information on COVID-19 vaccination in your area. It is important for people with medical conditions and their providers to work together and manage those conditions carefully and safely. Get a COVID-19 vaccine as soon as you can. If you have a medical condition, the following are actions you can take based on your medical conditions and other risk factors:
美國食品及藥物管理局(FDA)7日通過首款有助於減緩阿茲海默症(Alzheimer's disease)認知退化的藥物。研究證明，美國藥廠百健(Biogen)研發、名稱為Aducanumab的新藥，可以讓阿茲海默症引起的輕度認知障礙及早期失智症(dementia)，雙雙獲得改善。根據估計，每名阿茲海默症患者使用Aducanumab，一年下來估計花費為5萬元。 華盛頓郵報指出，這是第一款證實可以減緩腦部功能退化而獲得食藥局通過的新藥，不只是僅僅能夠舒緩症狀而已。從2003年以來，並沒有任何阿茲海默症獲得食藥局通過，由此可見阿茲海默症藥物研發失敗率極高。 Aducanumab新藥研發過程中，曾引發正反兩派論戰。支持者認為，這款藥品獲得食藥局核可之後，可望引來各界對於阿茲海默症更高關注，進而帶動對於治療阿茲海默症解方的更多研究與投資。 百健藥廠表示，Aducanumab的問世能讓阿茲海默症患者爭取到更多寶貴時間與家人相處，患者的日常生活也可以自理，例如清潔、購物等。 Aducanumab是實驗室研發的蛋白質「單株抗體」(monoclonal antibody)，必須透過靜脈注射，啟動患者體內的反疫反應，清除腦部澱粉蛋白斑塊。百健藥廠強調，這款藥品並不會治好阿茲海默症。 然而，反對派人士則表示，Aducanumab藥品是否確實有效，數據資料薄弱，食藥局為這款新藥放行，反映出主管機關迫於病患及倡議團體壓力之下，降低審查標準。 「阿茲海默症協會」(Alzheimer's Association)指出，美國目前約有620萬名阿茲海默症患者，如果沒有突破療法出現，患者人數到了2050年可望翻倍。 文章來源：www.worldjournal.com/wj/story/121469/5516439 FDA’s Decision to Approve New Treatment for Alzheimer’s Disease By Dr. Patrizia Cavazzoni, Director, FDA Center for Drug Evaluation and Research
Today FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit. This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain. The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia. We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives. At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy. What the Data Show The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline. We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice. Accelerated Approval The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need. Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain). A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. The Devastation of Alzheimer’s Disease With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease. The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States. Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease. FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease. 文章來源：www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease?fbclid=IwAR2_dfZqAgfSkGGHOcLFtrZvjsTYuDvhB9kymPQr7C3y4pzi9vBLzw_XgRA 「新英格蘭醫學」(New England Journal of Medicine)網路期刊和美國臨床腫瘤醫學會(American Society of Clinical Oncology)發表的一項跨國研究發現，英國藥廠阿斯特捷利康公司 (AstraZeneca PLC) 與美國藥廠默克公司 (Merck & Co.) 銷售的藥物Lynparza，可減少早期具侵襲性乳癌女性患者的癌症復發機率。 這項長期研究是遺傳性癌症治療的最新發展，為人類對抗遺傳性乳癌增添生力軍；也證明製藥業花在新型藥物PARP抑製劑方面的昂貴投資，是值得的。 Lynparza藥在美國定價為每位患者每月1萬4449元，是阿斯特捷利康公司最暢銷產品之一，主要用於治療晚期BRCA基因突變乳癌；去年銷售額達18億元。其競爭對手葛蘭素史克(GlaxoSmithKline)2019年斥資逾50億元收購另一款PARP抑製劑Tesaro製藥廠。 阿斯特捷利康癌症部門執行副總裁弗雷德里克森(David Fredrickson)表示，阿斯特捷利康將把研究數據提交監管機構，請求批准將Lynparza用於早期BRCA基因突變乳癌治療。 PARP抑製劑的作用是截斷癌細胞修復自身DNA能力，並導致癌細胞死亡。近年來，衛生監管機構已批准此類藥物用於治療卵巢癌、乳癌、前列腺癌和胰腺癌。目前發現這些藥物對BRCA1和BRCA2基因突變癌症，特別有用。 有BRCA基因突變的女性，罹患乳癌風險更高且通常更年輕。基因突變約占美國每年確診28萬1000椿乳癌病例的5%。根據美國癌症協會數據，乳癌是女性罹癌死亡第二大原因，每年在美國造成約4萬3600人死亡。美國食品藥物管理局(FDA)已在2018年批准使用Lynparza治療晚期的BRCA基因突變乳癌。 治療3年 近86%未復發 此項研究從2014年開始，在美國和其他22個國家/地區有1836名罹患早期BRCA1或 BRCA2乳癌的女性，在參加研究前均接受過切除腫瘤手術，並在手術前後接受防止腫瘤復發的化療。根據腫瘤大小或存在於淋巴結的癌症情況，她們的復發風險都很高。 研究隨機分配一半女性每天服用Lynparza藥劑一年，另一半服用安慰劑；研究人員發現，治療開始後2年半的中位隨訪期內，與安慰劑相比，Lynparza降低了42%癌症復發或任何原因死亡的綜合風險。治療三年後，接受Lynparza治療的女性85.9%沒有復發，接受安慰劑的女性77.1%未復發。 以上文章內容摘自世界新聞網。www.worldjournal.com/wj/story/121187/5511226 Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer Abstract
BACKGROUND Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer. METHODS We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease–free survival. RESULTS A total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease–free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P<0.001). The 3-year distant disease–free survival was 87.5% in the olaparib group and 80.4% in the placebo group (difference, 7.1 percentage points; 95% CI, 3.0 to 11.1; hazard ratio for distant disease or death, 0.57; 99.5% CI, 0.39 to 0.83; P<0.001). Olaparib was associated with fewer deaths than placebo (59 and 86, respectively) (hazard ratio, 0.68; 99% CI, 0.44 to 1.05; P=0.02); however, the between-group difference was not significant at an interim-analysis boundary of a P value of less than 0.01. Safety data were consistent with known side effects of olaparib, with no excess serious adverse events or adverse events of special interest. CONCLUSIONS Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo. Olaparib had limited effects on global patient-reported quality of life. (Funded by the National Cancer Institute and AstraZeneca; OlympiA ClinicalTrials.gov number, NCT02032823. opens in new tab.) 原文出處：NEJM(www.nejm.org/doi/full/10.1056/NEJMoa21052155) 美國聯邦食品暨藥物管理局 (FDA) 4日核准一款糖尿病藥物Wegovy在美國販售，稱此藥可協助肥胖症患者進行長期減重；根據該藥物研究報告指出，使用Wegovy的試驗者平均減重15%，大約是34磅(15.3公斤)。 研究報告顯示，服用該藥物的受測者可在14個月內維持體重下滑，直到體重變化趨於穩定；至於服用安慰劑的對照組，受測者體重平均只減少2.5%，不超過六磅。 協助該藥物研究報告、路易維爾代謝與動脈粥狀硬化研究中心(Louisville Metabolic and Atherosclerosis Research Center)醫學主任貝斯(Harold Bays)表示：「市面上目前有的藥物只能幫助減重大約5%至10%，有時候甚至不到。」 全美罹患肥胖症的成人人口超過1億人，占比約三分之一；一般人若減重5%就能大幅改善行動力、高血壓、高血糖和膽固醇指數等健康問題；但貝斯表示，對肥胖症的患者來說，只減重5%是不夠的。 貝斯強調，比起一些初期用於治療肥胖症的藥物，Wegovy更加安全；Wegovy最常見的副作用包括腸胃不適、噁心、腹瀉和嘔吐，但這些症狀都會慢慢消退，但仍有5%的試驗者最終停止使用。 Wegovy對罹患特定甲狀腺瘤的患者具有潛在風險，因此不建議家族有甲狀腺瘤或內分泌瘤病史的人使用；此外，該藥物也會增加憂鬱症和胰臟發炎的風險。 Wegovy由丹麥藥廠諾和諾德(Novo Nordisk)研發，是一種用來抑制食慾的腸道激素，比另一款糖尿病用藥semaglutide的劑量還高；糖尿病患者每周使用一次Wegovy，並搭配飲食調整和運動達到減重的效果。 諾和諾德還未公布Wegovy的定價，但據稱和另一款減肥藥Saxenda的價格不相上下；Saxenda為每日注射，如果使用者沒有保險，一個月的費用在1300美元以上。(約39000元新台幣) 休士頓衛理公會醫院集團(Houston Methodist Hospitals)糖尿病首席醫師薩度(Archana Sadhu)表示，Wegovy的成效將取決於定價，因為有時候健保並不給付減肥藥物，定價太高恐怕使需要的人無法獲得。 以上文章內容摘自世界新聞網。www.worldjournal.com/wj/story/121617/5512354 提醒大家，此藥品在台灣尚未通過TFDA核准。 以下是美國FDA發表的新聞稿： (該新聞稿網址： https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014) FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. This under-the-skin injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. “Today’s approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program,” said John Sharretts, M.D., deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight.” Approximately 70% of American adults have obesity or overweight. Having obesity or overweight is a serious health issue associated with some leading causes of death, including heart disease, stroke and diabetes, and is linked to an increased risk of certain types of cancer. Losing 5% to 10% of body weight through diet and exercise has been associated with a reduced risk of cardiovascular disease in adult patients with obesity or overweight. Wegovy works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects. Wegovy should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists, or other products intended for weight loss, including prescription drugs, over-the-counter drugs, or herbal products. Wegovy has not been studied in patients with a history of pancreatitis. Wegovy’s safety and efficacy were studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials (including 16 weeks of dose increases) and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients receiving Wegovy either continued with the treatment or switched to a placebo. More than 2,600 patients received Wegovy for up to 68 weeks in these four studies and more than 1,500 patients received placebo. The largest placebo-controlled trial enrolled adults without diabetes. The average age at the start of the trial was 46 years and 74% of patients were female. The average body weight was 231 pounds (105 kg) and average BMI was 38 kg/m2. Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received placebo. Another trial enrolled adults with type 2 diabetes. The average age was 55 years and 51% were female. The average body weight was 220 pounds (100 kg) and average BMI was 36 kg/m2. In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received placebo. The most common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection) and gastroesophageal reflux disease (a type of digestive disorder). The prescribing information for Wegovy contains a boxed warning to inform healthcare professionals and patients about the potential risk of thyroid C-cell tumors. Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Wegovy should not be used in patients with a history of severe allergic reactions to semaglutide or any of the other components of Wegovy. Patients should stop Wegovy immediately and seek medical help if a severe allergic reaction is suspected. Wegovy also contains warnings for inflammation of the pancreas (pancreatitis), gallbladder problems (including gallstones), low blood sugar, acute kidney injury, diabetic retinopathy (damage to the eye's retina), increased heart rate and suicidal behavior or thinking. Patients should discuss with their healthcare professional if they have symptoms of pancreatitis or gallstones. If Wegovy is used with insulin or a substance that causes insulin secretion, patients should speak to their health care provider about potentially lowering the dose of insulin or the insulin-inducing drug to reduce the risk of low blood sugar. Healthcare providers should monitor patients with kidney disease, diabetic retinopathy and depression or suicidal behaviors or thoughts. The FDA granted the approval to Novo Nordisk. Semaglutide 1 mg injection (Ozempic) was first approved as a treatment for type 2 diabetes in 2017. Related Information NIH: Overweight & Obesity Statistics ### The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. 有關該藥品的詳細說明，僅供專業醫療人員閱覽，恕不對外開放。 此文合乎著作權法第50條規定：「以中央或地方機關或公法人之名義公開發表之著作，在合理範圍內，得重製、公開播送或公開傳輸。」
很多人問到關於GLP-1 RA的使用上，對於低血糖的副作用相對的非常少，到底是甚麼緣故呢？ 根據美國糖尿病醫學會的這篇文獻來看，可以發現不論是原生的GLP-1或是GLP-1 RA，都可以雙向的刺激或是抑制α細胞，進而調控昇糖素。 也因此當血糖濃度較高時，會抑制α細胞，減少昇糖素分泌，同時刺激β細胞，增加胰島素分泌。 當血糖濃度較低時，則顛倒過來，變成刺激α細胞，增加昇糖素分泌，同時減少刺激β細胞，減少胰島素分泌。 如此一來幫助達到良好血糖控制，也不容易造成低血糖問題。 GLP-1 (via GLP-1R in α-cells) plays a bidirectional role, either stimulatory or inhibitory, in glucagon secretion depending on glucose levels. GLP-1（透過阿發細胞中的GLP-1R）根據血中葡萄糖濃度調控昇糖素分泌達到刺激或抑制作用 GLP-1 RA (包括 liraglutide, semaglutide, dulaglutide, 及 albiglutide) 更詳細內容 於專業人員區。 資料來源：GLP-1 Receptor in Pancreatic a-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner  Isolated islets from αGLP-1R−/− mice show abnormal glucagon secretion in response to glucose. Islets were isolated from female mice, 3–4 months old, and used in these experiments. Shown are average data from at least three independent assays, which involved 8–10 mice/group. A: GSIS assay of islets isolated from the KO (ko) and WT (wt) mice. Low (L) glucose: 2.5 mmol/L; high (H) glucose: 16.5 mmol/L. B: The stimulation index (S.I.) of GSIS, which was calculated by dividing the insulin concentration at high glucose by that at low glucose. C: Arginine (Arg)-stimulated glucagon secretion assay, which used 20 mmol/L arginine and 100 nmol/L exendin9-39 (Exe9-39). D: Stimulation indexes for glucagon by arginine, exendin9-39, and both arginine and exendin9-39. Glucagon (E) and insulin (F) secretion in response to glucose levels of 2.5 mmol/L, 5 mmol/L, and 10 mmol/L. *P < 0.05; **P < 0.01.
Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review Henri Honka, Carolina Solis-Herrera, Curtis Triplitt, Luke Norton, Javed Butler, and Ralph A. DeFronzo J Am Coll Cardiol. 2021 Apr, 77 (16) 2022–2039  Abstract The mechanisms responsible for the positive and unexpected cardiovascular effects of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes remain to be defined. It is likely that some of the beneficial cardiac effects of these antidiabetic drugs are mediated, in part, by altered myocardial metabolism. Common cardiometabolic disorders, including the metabolic (insulin resistance) syndrome and type 2 diabetes, are associated with altered substrate utilization and energy transduction by the myocardium, predisposing to the development of heart disease. Thus, the failing heart is characterized by a substrate shift toward glycolysis and ketone oxidation in an attempt to meet the high energetic demand of the constantly contracting heart. This review examines the metabolic pathways and clinical implications of myocardial substrate utilization in the normal heart and in cardiometabolic disorders, and discusses mechanisms by which antidiabetic drugs and metabolic interventions improve cardiac function in the failing heart. Highlights • Bioengineering of cardiac metabolism represents a novel strategy to improve cardiac function and slow the progression of myocardial disease. • Modification of myocardial metabolism by SGLT-2 inhibitors, GLP-1 RAs, and pioglitazone can reduce CV events in patients with type 2 diabetes. • The potential benefit of shifting fuel utilization pathways in patients with HF should be investigated in future trials. SGLT-2i和 GLP-1 RA在2型糖尿病患者中產生積極心血管保護作用的機制仍有待確定。這些抗糖尿病藥物之有益心臟作用可能是因改變心肌代謝所引導的。常見的代謝異常，包括代謝（胰島素阻抗）症候群和2型糖尿病，與心肌基質利用率和能量傳遞的改變有關，而導致易患心臟病。因此，衰竭的心臟的特徵在於基質之糖分解和酮氧化的轉變，產生更多高能量，以合乎衰竭的心肌需求。 重點摘要： 1、心臟代謝的生物工程學顯示一種改善心功能並減慢心肌疾病進展的新策略。 2、SGLT-2i，GLP-1 RA對心肌代謝的改變可以減少2型糖尿病病患者的心血管事件。 3、將來的試驗中應研究改變燃料利用途徑對心衰竭患者的潛在益處。 Metformin與心臟 臨床實驗，降低患有心血管疾病的重大不良心血管事件。(但臨床試驗者較少) 此部分可能還需要更多臨床受試者來提供數據。 Thiazolidinediones (TZDs)與胰島素阻抗症候群 臨床實驗，降低患有心血管疾病併有第二型糖尿病的重大不良心血管事件。 藉由改善左心室舒張漢收縮功能、改善胰島素刺激的葡萄糖吸收以及降低脂毒性並增加支防氧化。 SGLT-2i，(Thrifty Substrate Hypothesis) (包括 empagliflozin，canagliflozin和dapagliflozin) 臨床實驗，降低患有心血管疾病併有第二型糖尿病的重大不良心血管事件，也降低心衰竭的風險。 對於非第二型糖尿病併有心臟衰竭是指左心室射出率低下的的住院風險也有所降低。. 由於目前僅是假說，所以還等待更多醫學臨床的實證。 (可能是酮生成與心肌對酮的吸收變強，進而改善心肌功能) GLP-1 RA(包括 liraglutide, semaglutide, dulaglutide, 及 albiglutide)和心臟保護 臨床實驗，降低患有心血管疾病併有第二型糖尿病的重大不良心血管事件，也降低心衰竭的風險。 GLP-1 RA主要可防止缺血再灌注損傷，也可增加心跳，可歸因於刺激竇房結。如果心跳加快是由副交感神經刺激引起的，則可能是GLP-1 RA類對心臟的保護作用。 減肥手術/熱量限制 由於在現實中實現長期的飲食熱量限制是非常難，因此減肥手術後的結果雖然是初步的，但仍需進行長期的研究，以檢查手術引起的體重減輕對心功能和心衰竭的影響。 更詳細內容 於專業人員區。
資料來源： J Am Coll Cardiol 2021, 77(16) 2022-2039 新德大藥局聲明： 本藥局(新德大藥局)近日發現有不肖人士未經本藥局及陳信潔藥師同意，擅自盜用圖片以及影片，於臉書FB以及網路刊登廣告，並非法於網路販售藥品。 本藥局特此鄭重澄清，本藥局並未於網路販售藥品，請網友切勿受欺上當。為保障本藥局及陳信潔之權益，本藥局將追查不法盜用者之法律責任。 新德大藥局 110年3月28日    《最值得關注的藥物預測》（Drugs to Watch）年度報告，在2021年已核准或即將核准的新藥和生物製劑中列出了4種可能暢銷的藥物，分別來自慢性、持續進展以及使人衰弱的疾病治療藥物：
阿茲海默症治療藥物--Aducanumab 全球約有5千萬名阿茲海默症患者，阿茲海默症患者通常在 65 歲以後才被診斷出來，但在出現症狀之前，病患的大腦往往退化已經數年、甚至數十年。 阿茲海默症患者的病徵是大腦出現病變，如「β澱粉類蛋白」異常聚集，這種現象多在患者出現阿茲海默症的明顯症狀前20年開始出現。由美國藥廠Biogen和Eisai共同開發的Aducanumab，主要是針對這些致病的機轉來進行標靶藥物開發，目標能緩解退化現象。 而Aducanumab被視為是最有機會不能通過的藥品，雖然在2020年7月向美國食藥局（FDA）申請上市，但之後卻被FDA認為證據不足。 最新進展是，Biogen和Eisai於今年1月底宣布，已接獲FDA延長生物製劑許可證申請（BLA）的通知，將盡力提供更多分析與臨床數據。 乾癬治療藥物--bimekizumab 乾癬的全球患病率約為2%-3%，並且可能引發身上其他的自體免疫疾病。由UCB研發的bimekizumab雖然上市時間較晚，但其療效優於目前的用藥，且嚴重副作用較少，因此預期該藥具有最佳療效。 前列腺癌口服藥--Relugolix 前列腺癌是全球男性的第二大常見惡性腫瘤，由武田研發的Relugolix是口服製劑首創（first-in-class）新藥，比起注射用的藥品相比，口服製劑更具優勢。同時，Relugolix也可用於治療困擾數百萬女性的子宮內膜異位症和子宮肌瘤，被看好能增加該藥品成功上市且大量使用的機率。 心衰竭治療藥物--Vericiguat 拜耳和默克聯合研發的Vericiguat是一種治療心衰竭的創新藥物，也是首款專門針對射血分數降低的慢性心衰竭（HFrEF）高危險族群的治療藥物。 這項報告在2021年達到臨床二期或以上階段的的藥物，製作出年度潛力暢銷藥物列表，並通過查詢年度報告、藥物產品線、臨床試驗、專利、化學資訊、交易、監管狀況等，對每種藥物進行了研究和評估。 Among new drugs and biologics that have either won approval or are on the cusp of doing so, Clarivate has identified four treatments that are likely to achieve blockbuster status, delivering annual sales of more than $1 billion, within five years. The 2021 Drugs to Watch include:
關鍵字：Aducanumab、阿滋海默症、Relugolix、前列腺癌、bimekizumab、乾癬、Vericiguat、心衰竭、CHF、Alzheimer、psoriasis 資料來源：Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021 https://clarivate.com/cortellis/news/clarivate-drugs-to-watch-report-highlights-four-likely-blockbusters-among-drugs-launching-in-2021/ 各項藥品之完整文章依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。 恕不對外開放非專業人士使用。 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 心衰竭是由於心髒結構，及/或功能異常，且證實利鈉肽 (Natriuretic peptide)升高，及/或肺或系統循環充血，而引起之臨床症候與症狀。 （3/1/2021 Journal of Cardiac Failure, European Journal of Heart Failure) 用白話文說，就是： 心衰竭是由於 1、心臟結構異常，或 2、心臟功能異常 且有： 1、利鈉肽 (Natriuretic peptide)升高，或 2、肺/系統循環鬱血 引起的臨床症狀/症候群。 這個定義來自於以下各國心臟學會達成的共識： 1、歐洲心臟學會的心衰竭協會 2、日本心衰竭學會 3、加拿大心衰竭學會 4、澳洲紐西蘭心臟學會 5、中國心衰竭協會 哈佛醫學院的Braunwald 及Antman 在該期刊社論也加以肯定。看來，這個定義是一統江湖的新主流了。 過去30年，心衰竭被定義為，心臟無法負荷新陳代謝所需而引起之症狀。相較之下，新定義確實著重於「心臟」因素。 特別注意的是，按照新定義，因為慢性腎病(CKD)所造成的水份滯留，並不包括在心衰竭之內。 心衰竭的階段分期(staging) 有了新定義，staging也跟著修改。 發生心衰竭風險(At-risk for HF)(A期)： 病人有發生心衰竭風險，但以前或現在心臟並無結構或功能異常的症狀，也沒有利鈉肽升高的情形。 心衰竭前期(Pre-HF)(B期)： 以前至目前無心衰竭症狀，但有心臟結構/功能異常存在，或利鈉肽升高情形。 心衰竭(C期)：以前或現在已出現因為心臟結構/功能異常的症狀。 晚期(嚴重)心衰竭(Advanced HF)(D期)： 病人在靜態休息時出現嚴重的症狀，經指引導向治療仍重覆住院，且需要進一步的治療，如換心，機械循環輔助，或緩和醫療(palliative)。 值得注意的是，心衰竭前期(Pre-HF)(B期)。這個概念就如同癌前期，仍然可以治療，可以預防的。就像糖尿病而且有心衰竭風險的病人，使用SGLT2 一樣。 面對使用左心室射出分率(LVEF)來分類心衰結治療，如低射出分率(HFrEF, Heart Failure with reduced ejection fraction)，及正常射出分率(HFpEF, Heart Failure with Preserved Ejection Fraction), 新定義的心衰竭也有更新版的說法： 低EF的心衰竭(HFrEF)：LVEF在40%以下 輕度低EF的心衰竭(HFmrEF)：LVEF 41-49% 正常射出分率(HFpEF)： LVEF大於50% 改善射出分率之心衰竭(HFimpEF)：從基本EF小於等於40%，提升至少10點，且第二次測量之EF大於40% 最後一項的改善射出分率之心衰竭，觀念上是提醒人們，心衰竭治療後，是可以改善(improve)的，而不是恢復(recover)。 新定義是強調，心衰竭是連續演變的事情(continuum)，而不是只去不回的單行道。 在治療角度觀之，過渡性的EF 改變，即使提升10-20%，如果沒有超過達到EF40%，治療策略不需要改變。如果EF升高超過40%，治療策略需要調整。 雖然論文發表時用的標題是《Universal Definition》Braunwald 認為新的定義還不能說全球共識，因為美國心臟協會(AHA)及美國心臟學院並未參與。 新定義還需時間考驗。 關鍵字：心衰竭、heart failure、高血壓、肺動脈高壓 資料來源： 臨床筆記 Universal definition and classification of heart failure. J Cardiac Fail 2021;00:1-27 若有任何問題或需要驗證通過專業人員區，都歡迎加官方LINE帳號(點此即可加入)詢問。 |
依主管機關相關規定，專業醫藥資訊僅提供醫藥專業人員參考(請申請核可通過後，即可閱讀專業人員區)。
恕不對外開放非專業人士使用。 每月文章
十一月 2022
類別 |
RSS 訂閱
營業時間：週一至週日(全年無休) 早上九點至晚上十一點四十分 (09：00~23：40)
|
地址：台北市松山區饒河街204號
|
聯絡我們
|